References
- Rosenberg B Van Kamp L Krigas T . Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature205 (4972), 698–699 (1965).
- Kelland L . The resurgence of platinum based cancer therapy. Nat. Rev. Cancer7 (8), 573–584 (2007).
- Cancer Gov www.cancer.gov/cancertopics/druginfo/cisplatin.
- Siddik ZH . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22, 7265–7279 (2003).
- Boulikas T Pantos A Bellis E Chritofis P . Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther.5 (2007), 537–583 (2007).
- Shen DW Pouliot LM Hall MD Gottesman MM . Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev.64 (3), 706–721 (2012).
- Azzoli CG Kris MG Pfister DG . Cisplatin versus carboplatin for patients with metastatic non–small-cell lung cancer—An old rivalry renewed. J. Natl. Cancer Inst.99 (11), 828–829 (2007).
- Stathopoulos GP Boulikas T . Lipoplatin formulation review article. J. Drug Deliv.https://doi.org/10.1155/2012/581363 (2012).
- Ravaioli A Papi M Pasquini E et al. Lipoplatin monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J. Chemother.21 (1), 86–90 (2009).
- Regulon www.regulon.org/prs/pdf/2.pdf.
- Seetharamu N Kim E Hochster H Martin F Muggia F . Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res.30 (2), 541–546 (2010).
- Kim ES Lu C Khuri FR et al. A phase II study of stealth cisplatin (SPI-77) in patients with advanced non-small lung cancer. Lung Cancer34 (3), 427–432 (2001).
- de Jonge MJ Slingerland M Loos WJ et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer46 (16), 3016–3021 (2010).
- Clinical Trials www.ClinicalTrials.gov.
- Haxton KJ Burt HM . Polymeric drug delivery of platinum-based anticancer agents. J. Pharm. Sci.98 (7), 2299–2316 (2009).
- Uchino H Matsumura Y Negishi T Koizumi F Hayashi T Honda T Nishyama N Kataoka K Naito S Kakizoe T . Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer93 (6), 678–687 (2005).
- Cheng L Jin C Lv W Ding Q Han X . Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS ONE6 (9), e25433 (2011).
- Deng ZJ Morton SW Ben-Akiva E Dreaden EC Shopsowitz KE Hammond PT . Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano7 (11), 9571–9584 (2013).
- Haxton KJ Burt HM . Hyperbranched polymers for controlled release of cisplatin. Dalton Trans.43, 5872–5875 (2008).
- Comenge J Sotelo C Romero F Gallego O Barnadas A Parada GC Dominguez F Puntus VF . Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS ONE7 (10), e47562 (2012).
- Valencia PM Pridgen EM Perea B et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine8 (5), 687–698 (2012).
- Sengupta P Basu S Soni S et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl Acad. Sci. USA109 (28), 11294–11299 (2012).
- Babu A Wang Q Muralidharan R Shanker M Munshi A Ramesh R . Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol. Pharm.11 (8), 2720–2733 (2014).